Video

CDK4/6 Inhibition's Role in HR+ Metastatic Breast Cancer

Transcript:

Transcript Edited for Clarity

Related Videos
Sunil Adige, MD
Seth Wander, MD, PhD
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Cynthia X. Ma, MD, PhD
Ann H. Partridge, MD, MPH
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Virginia Kaklamani, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Related Content
FDA
October 10th 2024

FDA Approves Inavolisib Plus Palbociclib/Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Advanced Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California, as well as a health sciences clinical professor at the University of California, Los Angeles
October 8th 2024

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29

Yuan Yuan, MD, PhD, a professor of medicine, the director of Breast Oncology, and the medical director of the Breast Oncology Disease Research Group at Cedars-Sinai Medical Center in Los Angeles, California. She is also a health sciences clinical professor at the University of California, Los Angeles.
October 5th 2024

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests